Best Neurology Companies in Sweden
The 51 best Neurology companies in Sweden in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Abliva.
- Neurology Market Expected to Witness Sustained Growth
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Neurology companies in Sweden
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Abliva Developer of drugs to treat multiple neurological disorders | $23M | 50 mo ago | 8 | — | WordPress Block EditorWordPressMySQL+14 | Top 10M | 50 patents Cell-permeable succinate prodrugs and quinone therapies for metabolic and RBC disorders | — |
| 2 | PharmNovo Developer of a novel drug for neuropathic pain relief solutions | $21M | 24 mo ago | 9 | Bengt Mentzer Founder & President | — | — | 25 patents Pharmaceutical solid‑form polymorphs of opioid agonist salts and related delta‑opioid ligands | 1 launch |
| 3 | Umecrine Cognition Developer of therapeutics for hepatic encephalopathy | $18M | 15 mo ago | 3 | Viktor Drvota CEO | — | — | 117 patents Neurosteroid GABAA‑α3 modulators and their pharmaceutical formulations | — |
| 4 | TikoMed Developers of regenerative medicine for cell therapies | $15M | 76 mo ago | 7 | — | — | — | 31 patents Peptide-coated medical implants to prevent fibrotic tissue formation | — |
| 5 | Flow Neuroscience Provider of a wearable device for stress and anxiety management | $12M | 59 mo ago | 21 | — | WagtailPythonDjango+25 | Top 500k | 33 patents Non‑invasive transcranial direct‑current stimulation headsets and electrode positioning systems | 1 launch |
| 6 | IRRAS Provider of devices for fluid control and management after surgery | $11M | 122 mo ago | 52 | Will Martin CEO | WordPress Block EditorWordPressMySQL+20 | Top 50M | 33 patents Medical fluid exchange catheters for intravascular therapy and sensing | — |
| 7 | 2A Pharma Developing vaccine using adeno-associated virus-like particle technology for cancer and infectious diseases. | $5M | 97 mo ago | 10 | Preben Bruun-Nyzell CEO | — | — | 10 patents Therapeutic parvovirus-derived proteins for autoimmune and HPV treatment | — |
| 8 | MedVasc Providing a surgical tool for intraoperative drug delivery | $4M | 6 mo ago | 4 | Michael Akesson Founder | — | — | 15 patents Intravascular and cavity ablation devices for treating defective vessels, cavities, and ducts | — |
| 9 | Likvor System for cerebrospinal fluid system (neurological) investigations | $3M | 126 mo ago | 6 | — | — | — | 11 patents Cerebrospinal fluid monitoring and automated shunt regulation technologies | — |
| 10 | Integrative Research Laboratories Using systems pharmacology to develop small molecule therapeutics for neurodegenerative diseases | $3M | 67 mo ago | 33 | — | WordPress Block EditorWordPressMySQL+13 | Top 50M | — | — |
| 11 | AlzeCure Pharma Developer of therapeutics for neurological disorders | $3M | 8 mo ago | 11 | — | WordPressMySQLPHP+24 | Top 10M | 68 patents Patents concentrated in chemistry & materials | 5 partnerships |
| 12 | Abarceo Developer of therapeutics for type-2 diabetes and other diseases | $3M | 65 mo ago | 8 | Kristian Hansen Chief Executive Officer | — | — | 5 patents Design of small‑molecule inhibitors targeting VDAC1 for therapeutic applications | — |
| 13 | Umecrine Developer of drugs to treat neurological disorders of the brain | $2M | 19 mo ago | — | Torbjorn Backstrom CEO | — | — | 72 patents Steroid-based compounds modulating GABAA α3 receptors for neurological therapeutics | — |
| 14 | Amniotics Developer of stem cell based therapies for multiple disorders | $2M | 40 mo ago | 14 | Marcus Larsson Co-Founder | — | — | 54 patents Patents concentrated in chemistry & materials | — |
| 15 | Uman Sense Developer of wearable device for stroke detection | $2M | 23 mo ago | 9 | Johan Wasselius Co-Founder | — | — | 9 patents Wearable/implantable sensors for real-time stroke detection and monitoring in patients | — |
| 16 | 2N Pharma Developer of therapeutics for treating ALS | $2M | 70 mo ago | 14 | Preben Nyzell Co-Founder & CEO | — | — | 10 patents Therapeutic parvovirus capsid proteins for autoimmune disease and HPV treatment | — |
| 17 | Gabather Developer of therapeutics for neuropsychiatric disorders | $1M | 134 mo ago | 3 | Michael-Robin Witt Chief Executive Officer | UmbracoHighstockHighcharts+16 | Top 50M | 15 patents Synthesis of triazoloquinazolinone heterocycles and lipid drug‑delivery formulations. | — |
| 18 | Edvince Swedish, early stage company developing emergency treatments for Stroke victims | $643K | 55 mo ago | 4 | Lars Edvinsson Founder | — | — | 17 patents Small-molecule MEK/PKC kinase inhibitor therapeutics for acute stroke treatment | — |
| 19 | Medfield Diagnostics Systems for pre-hospitalization diagnostics of brain injuries | $641K | 83 mo ago | 8 | — | WordPress Block EditorWordPressMySQL+11 | Top 10M | 22 patents Non‑invasive RF/microwave scattering diagnostics for internal object detection and tissue characterization. | — |
| 20 | Sinntaxis Developer of small molecule based therapeutics for the treatment of stroke recovery | $219K | 68 mo ago | — | Tomas Eriksson CEO | — | — | 11 patents Negative allosteric modulators of mGluR5 for neuroprotective treatment of mature brain injury | — |
| 21 | Alzinova Early-stage, public, Swedish Biotech company developing oligomer-directed vaccine and mAbs for Alzheimers'… | $164K | 107 mo ago | 4 | Anders Sandberg Co-Founder | WordPressMySQLPHP+16 | Top 10M | 24 patents Humanized antibodies targeting amyloid‑beta 42 for Alzheimer's disease treatment | 1 partnership |
| 22 | Sinfonia Biotherapeutics Developer of therapeutics to treat neurological diseases | $112K | 86 mo ago | — | Lars Wahlberg Founder & CEO | — | — | — | — |
| 23 | FluoLink Developer of a fluorescence-based spectroscopy system to detect brain cancer | $107K | 88 mo ago | — | Johan Richter Co-Founder | — | — | 4 patents Optical biopsy guidance probes for tissue identification and harvesting | — |
Top 12 Neurology companies in Sweden
#1
Series A · Lund, Skane County · founded 2013 · 4 employees$3.7Mraised▾
MedVASC AB is providing a surgical tool for intraoperative drug delivery. They made a single cut through laser or catheter then puncture the vein wall through an anesthetic needle to numb the surrounding tissue. Through the fast treatment, surgery time is reduced by a half.
- Jan 2026Series A$2.6M
- May 2025Seed$1M
#2
Series A · Solna, Stockholm County · founded 2006 · 3 employees$18.3Mraised▾
Developer of therapeutics for hepatic encephalopathy (HE). Its proprietary platform uses small molecules that inhibit the action of GABA-steroids in the brain. Its lead candidate GR3027 is currently in phase 2a of clinical trials and can be used in both acute life-threatening HE, as well as minimal chronic HE.
- May 2025Grant (prize money)$420K
- Mar 2023Series A$3M
- Sep 2022Series A$3.9M
- Jul 2021Series A$4.1M
#3
Funding Raised · Huddinge, Stockholm County · founded 2016 · 11 employees$2.9Mraised▾
Developer of therapeutics for neurological disorders. It offers lead candidate ACD856 a positive modulator of Trk-receptors from the NeuroRestore platform for the treatment of Alzheimer's, Parkinson's disease, and related neurological diseases.
- Dec 2025Grant (prize money)$2.9M
#4
Series A · Lund, Skane County · founded 2008 · 9 employees$20.9Mraised▾
Developer of a novel drug for neuropathic pain relief solutions. It focuses on creating treatments without the side effects of conventional opioids. It is currently preparing for phase two studies with its lead candidate. It aims to provide effective neuropathic pain relief.
- Jul 2024Series A$16.3M
- Jul 2024Grant (prize money)$2.7M
- Jun 2022Seed$2M
- Nov 2020Seed$2.5M
#5
Seed · Umea, Vasterbotten County · founded 2000$2.4Mraised▾
Developer of drugs to treat neurological disorders of the brain. The pipeline includes a new class of drugs to alleviate cognitive symptoms caused by various underlying conditions. It offers GABA-A receptor modulating compounds for the treatment of anxiety and mood, memory, depression, overeating and regulation of satiety and appetite.
- Dec 2024Seed$2.2M
- Jan 2017Grant (prize money)$277.5K
#6
Seed · Lund, Skane County · founded 2018 · 9 employees$1.7Mraised▾
The company develops wearable device for stroke detection that consists of two bracelets with sensors and wireless communication with a smartphone. The Stroke Alarm provides an early indication of suspected stroke so that the victim can access care in time for treatment.
- Aug 2024Seed$289.5K
- Oct 2020Seed$716.8K
- Jan 2020Seed$528.4K
- May 2019Grant (prize money)$55.8K
#7
Acquired · Lund, Skane County · founded 2000 · 8 employees$23.4Mraised▾
Developer of drugs to treat multiple neurological disorders. The company has developed KL1333 (NAD+ regulator) that helps in the treatment of chronic primary mitochondrial diseases such as MELAS-MIDD spectrum disorders and PEO-KSS spectrum disorders. It provides NVP025 that is used for the treatment of mitochondrial myopathies. The company's other drug candidate includes NeuroSTAT that is used to treat traumatic brain injury (TBI), NV354, and others.
- Jun 2022Post IPO$20.4M
- Mar 2019Post IPO$3M
#8
Series A · Malmo, Skane County · founded 2016 · 21 employees$11.9Mraised▾
Provider of a wearable device for stress and anxiety management. The platform provides a Flow neural stimulator headset for depression treatment. The device tDCS headset delivers a gentle current to the forehead to reverse the activity imbalance observed in people with depression and training the brain to kick negative behaviours. The mobile app also provides exercises, meditation, and mindfulness programs.
- Aug 2021Series A$9.3M
- Jul 2019Seed$1.5M
- Jan 2018Seed$1.1M
- Sep 2017Seed—
#9
Public · Viken, Skane County · founded 2002 · 7 employees$14.7Mraised▾
Developer of regenerative medicines for cell therapies. Its leading candidate IBsolvMIR for regenerative cell therapies to treat severe diabetes and chronic pancreatitis; the second TM-500 for MS and neurological diseases; and ILB used for neurological disease caused by glaucoma.
- Mar 2020Series A$5.6M
- Feb 2019Series A$9.1M
#10
Seed · Lund, Skane County · founded 2015 · 14 employees$2.1Mraised▾
Developer of stem cell-based therapies for multiple disorders. The product PulmoStem is used for the treatment of severe inflammatory, fibrotic, brain, skin, kidney, and blood disorders. The company is harvesting and propagating tissue relevant neonatal quality mesenchymal stem cells for applications in regenerative medicine.
- Apr 2023Grant (prize money)$875.6K
- Jan 2022Grant (prize money)$526K
- Jun 2019Seed$2.1M
#11
Acquired · Stockholm, Stockholm County · founded 2012 · 52 employees$11.2Mraised▾
IRRAS develops devices for fluid control and management for several brain pathologies, CNS therapeutic applications, and procedures. Its products include instruments and catheters for the clinical, monitoring and surgical applications for brain pathology indications. Its flagship products IRRAflow provides, dynamic control of brain fluids, for irrigation and aspiration, precise infusion of fluids and intracranial pressure monitoring. It can be used for the treatments for infections and malignant tumors such as Ventriculitis, Meningitis, Abscesses and Osteomyelitis of the skull, and others.
#12
Public · Gothenburg, Vastra Gotaland County · founded 2013 · 33 employees$3.4Mraised▾
Integrative Research Laboratories Sweden AB (IRL) is a Swedish privately held drug discovery and development company providing novel treatments in the field of primary neurodegenerative disorders. IRL is pursuing small molecule programmes targeting core disabilities in dementias, attention disorders and Parkinson’s disease using its unique systems pharmacology discovery approach, the Integrative Screening Process (ISP), to find new treatment solutions. IRL utilizes an in vivo systems pharmacology approach based on phenotypic screening, systematically implemented and seamlessly integrated throughout the drug discovery process in a process referred to as the Integrative Screening Process (ISP). Phenotypic screening has proven more successful than target based screening in generating first-in-class drugs within the CNS area (as published in Nature Reviews Drug Discovery, 2011, Jun 24). ISP is based on studies of physiological and pathophysiological mechanisms at the system level in the living brain and the effects of drugs and drug candidates on these mechanisms at the integrated level. A screening system is built on in vivo systems responses, combined with strong medicinal chemistry
- Dec 2020Post IPO$15.7M
- Feb 2019Grant (prize money)$56.9K
- Nov 2018Grant (prize money)$57K
- May 2018Post IPO$16M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Neuroscience & Neurotech is moving in Sweden
A read on the academic research around Neuroscience & Neurotech — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 356 Sweden-affiliated papers.
- Umeå University107
- Linköping University75
- Karolinska Institutet64
- Lund University40
- Uppsala University40
- Stimulation1→7
- Deep brain stimulation3→8
- Neurostimulation1→4
- Neurostimulation1→9
- Brain stimulation1→5
- Depression (economics)2→5
- Neuromodulation1→4
- Somatosensory system1→4
- Essential tremor3→5
- Stimulation6→7
Where neurotech is researched across Sweden
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.